Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer
Open Access
- 7 June 2017
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 51 (2) , 686-694
Abstract
Most patients with pancreatic ductal adenocarcinoma (PDAC) have unresectable cancers with a dismal prognosis, in which cohort chemotherapy is the primary treatment. T cell immune adaption is critical for tumor immune escape and prognosis of this disease. The present study aimed to determine the correlation between peripheral T cell subset distribution in patients with unresectable PDAC and their response to chemotherapy. Two hundred and twelve patients with unresectable PDAC were included whose blood samples were collected for analysis of T cell subsets, including CD3+, CD4+, CD8+, CD8+CD28+ and CD4+CD25+CD127 T cells by flow cytometry before and after gemcitabine-based chemotherapy. Enzyme-linked immunosorbent assay was used to detect the expression levels of tumor growth factor (TGF)-β1, interleukin (IL)-6 and IL-17A in the patients before and after chemotherapy. Univariate and multivariate analyses found that an initial CD4/CD8 ratio or T regulatory (Treg) cell level before any treatment was associated with the prognosis of unresectable PDAC. After two cycles of chemotherapy, there was no significant change in percentages of T cell subsets, except elevation to a higher level of CD3+ T cells. Decreased Tregs or CD4/CD8 ratio after two cycles of chemotherapy predicts a longer overall survival (OS). Levels of Tregs in stable disease (SD) and partial remission (PR) cases significantly decreased after chemotherapy, but increased in progressive disease (PD) patients. There was no correlation between Tregs and the expression level of either TGF-β1 or IL-6. IL-17A expression was elevated in Treg-decreased patients, whereas IL-17A was reduced in Treg-increased patients after chemotherapy. The circulating signature of T cell subsets can predict OS and chemotherapeutic response in patients with unresectable PDAC, and may be attributable to the plasticity of T cell subsets.Keywords
This publication has 49 references indexed in Scilit:
- Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?Oncotarget, 2016
- Cytotoxic Effects of Chemotherapy on Cancer and Immune Cells: How can it be Modulated to Generate Novel Therapeutic Strategies?Future Oncology, 2015
- Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with ChemotherapyAnnals of Surgical Oncology, 2014
- Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survivalPancreatology, 2014
- Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, ChinaCancer Letters, 2014
- The immune network in pancreatic cancer development and progressionOncogene, 2013
- Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancerCancer Letters, 2009
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- Pancreatic cancerThe Lancet, 2004
- Pancreatic cancer biology and geneticsNature Reviews Cancer, 2002